Adagene

Adagene ROE

The Return on Equity (ROE) of Adagene (ADAG) as of Nov 2, 2026 is -49.82 %. In the previous year, Return on Equity (ROE) was -66.16 % — a change of -24.70% (higher).

ROE

-49.82 %

YoY

-24.70%

Last updated:

In 2025, Adagene's return on equity (ROE) was -49.82 %, a -24.70% increase from the -66.16 % ROE in the previous year.

The Adagene ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
35.88 USD
Jan 1, 2019
30.34 USD
Jan 1, 2020
18.39 USD
Jan 1, 2021
-46.74 USD
Jan 1, 2022
-96.25 USD
Jan 1, 2023
-26.85 USD
Jan 1, 2024
-66.16 USD
Jan 1, 2025
-49.82 USD
The Adagene ROE history
YEARROEYoY
-49.82 %-24.70%
-66.16 %+146.37%
-26.85 %-72.10%
-96.25 %+105.91%
-46.74 %-354.22%
18.39 %-39.39%
30.34 %-15.45%
35.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adagene Stock analysis

What does Adagene do? Adagene Inc. develops monoclonal antibody drugs for cancer treatment in China, focusing on clinical-stage products. Its lead candidate ADG126, a masked anti-CTLA-4 mAb, is in phase 1b/2 trials for cancer. The company also advances ADG116, a fully human anti-CTLA-4 antibody using NEObody technology, in phase 1b/2 for solid tumors. ADG206 targets advanced metastatic solid tumors in phase 1, while ADG104, an anti-PD-L1 antibody, is in phase 2 development. Additional candidates include ADG125 for phase 2 studies, ADG138 for low-expressing tumors, and ADG152 for off-tumor toxicities, all in preclinical stages. The company's pipeline targets various cancer types through innovative antibody technologies. Adagene generates revenue through the development and commercialization of its antibody drug candidates. It focuses on clinical trials for products like ADG126, ADG116, and ADG104, aiming to secure partnerships with pharmaceutical companies for later-stage development and marketing. The company's products target advanced cancer treatments, appealing to oncology-focused pharmaceutical firms seeking novel therapies. ADG153, a masked anti-CD47 antibody, and CD28 T-cell engagers represent further pipeline opportunities for collaboration in oncology drug development. Adagene's business model centers on advancing its pipeline through clinical trials to attract potential partners. The company's focus on anti-CTLA-4, anti-PD-L1, and novel antibody technologies positions it for strategic collaborations. Its products target unmet needs in cancer treatment, particularly for resistant or metastatic tumors. The company's preclinical and clinical-stage candidates, including ADG138 and ADG152, are designed to address specific oncology challenges, making them attractive for pharmaceutical partnerships. Adagene is one of the most popular companies on Eulerpool.

ROE Details

Decoding Adagene's Return on Equity (ROE)

Adagene's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Adagene's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Adagene's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Adagene’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Adagene stock

Return on Equity (ROE) of Adagene is -49.82 % in 2025.

Return on Equity (ROE) of Adagene changed from -66.16 % to -49.82 %, representing a -24.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Adagene since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Adagene with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Adagene

All Key Metrics — Adagene